HK1036016A1 - Inhibitors of complement activation - Google Patents

Inhibitors of complement activation

Info

Publication number: HK1036016A1
Authority: HK; Hong Kong
Prior art keywords: factor; inhibitors; complement activation; antibody; complement
Prior art date: 1998-02-20

Application number

HK01106981A

Other languages

English (en)

Inventor

Michael S C Fung

Cecily R Y Sun

Bill N C Sun

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-20

Filing date

2001-10-04

Publication date

2001-12-21

2001-10-04 Application filed by Genentech Inc filed Critical Genentech Inc

2001-12-21 Publication of HK1036016A1 publication Critical patent/HK1036016A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Transplantation (AREA)
Mycology (AREA)
Rheumatology (AREA)
Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

HK01106981A 1998-02-20 2001-10-04 Inhibitors of complement activation HK1036016A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7532898P	1998-02-20	1998-02-20
PCT/US1999/003566 WO1999042133A1 (en)	1998-02-20	1999-02-19	Inhibitors of complement activation

Publications (1)

Publication Number	Publication Date
HK1036016A1 true HK1036016A1 (en)	2001-12-21

Family

ID=22124992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK01106981A HK1036016A1 (en)	1998-02-20	2001-10-04	Inhibitors of complement activation

Country Status (18)

Country	Link
US (1)	US7439331B2 (da)
EP (6)	EP2033659B1 (da)
JP (1)	JP4437192B2 (da)
KR (1)	KR100425965B1 (da)
CN (2)	CN101298481A (da)
AT (1)	ATE412431T1 (da)
AU (1)	AU762050B2 (da)
BR (2)	BR9909220A (da)
CA (1)	CA2321140C (da)
CY (1)	CY1108663T1 (da)
DE (1)	DE69939813D1 (da)
DK (2)	DK2033659T3 (da)
ES (3)	ES2446930T3 (da)
HK (1)	HK1036016A1 (da)
NZ (1)	NZ506920A (da)
PT (1)	PT1054693E (da)
SI (2)	SI2033659T1 (da)
WO (1)	WO1999042133A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7112327B2 (en)	1998-02-20	2006-09-26	Tanox, Inc.	Inhibition of complement activation
WO2004028479A2 (en) *	2002-09-25	2004-04-08	Genentech, Inc.	Nouvelles compositions et methodes de traitement du psoriasis
AU2003302386B2 (en) *	2002-11-26	2010-04-01	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
DK1713503T3 (da)	2004-02-10	2013-11-04	Univ Colorado Regents	Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
US8911733B2 (en)	2005-05-26	2014-12-16	Musc Foundation For Research Development	Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
WO2007056227A2 (en) *	2005-11-04	2007-05-18	Genentech, Inc.	Use of complement pathway inhibitors to treat ocular diseases
WO2007141004A1 (en) *	2006-06-09	2007-12-13	Bayer Healthcare Ag	Use of adipsin (adn) as a therapeutic or diagnostic target
JP5250548B2 (ja)	2006-06-21	2013-07-31	エムユーエスシーファウンデーションフォーリサーチディベロップメント	疾患の治療のための補体ｈ因子の標的化
DK2097455T3 (da) *	2006-11-02	2014-12-15	Genentech Inc	Humaniserede anti-faktor d-antistoffer
EP1920781B1 (en) *	2006-11-10	2015-03-04	Glycotope GmbH	Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
HUE026001T2 (en) *	2007-02-05	2016-04-28	Apellis Pharmaceuticals Inc	Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
CA2680344A1 (en)	2007-03-14	2008-11-20	Woodruff Emlen	Humaneered anti-factor b antibody
AR066660A1 (es) *	2007-05-23	2009-09-02	Genentech Inc	Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
KR101572700B1 (ko) *	2007-06-07	2015-11-30	제넨테크, 인크.	보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
CR20170001A (es) *	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
AU2010266127B2 (en)	2009-07-02	2015-11-05	Musc Foundation For Research Development	Methods of stimulating liver regeneration
EP2496259B1 (en)	2009-11-05	2017-02-22	Alexion Pharmaceuticals, Inc.	Treatment of paroxysmal nocturnal hemoglobinuria
AU2011252864B2 (en)	2010-05-14	2015-11-05	The Regents Of The University Of Colorado, A Body Corporate	Improved complement receptor 2 (CR2) targeting groups
KR20130036276A (ko)	2010-06-22	2013-04-11	더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트	보체 결합 3의 C3d 조각에 대한 항체들
WO2013177035A2 (en)	2012-05-24	2013-11-28	Alexion Pharmaceuticals, Inc.	Humaneered anti-factor b antibody
AU2013302441B2 (en)	2012-08-17	2018-05-10	The Regents Of The University Of Colorado, A Body Corporate	Compositions and methods for detecting complement activation
US10413620B2 (en)	2012-08-17	2019-09-17	The Regents Of The University Of Colorado, A Body Corporate	Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
EP2912065A4 (en) *	2012-10-25	2016-10-19	True North Therapeutics Inc	ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
ES2514165B1 (es) *	2013-03-27	2015-09-09	Consejo Superior De Investigaciones Científicas (Csic)	Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
EP3290922A1 (en)	2013-08-07	2018-03-07	Alexion Pharmaceuticals, Inc.	Atypical hemolytic uremic syndrome (ahus) biomarker proteins
PE20160192A1 (es)	2013-08-12	2016-04-27	Genentech Inc	Composiciones y metodo para tratar condiciones asociadas con el complemento
BR112016025312A2 (pt)	2014-05-01	2017-10-17	Genentech Inc	variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
EP3137908B1 (en) *	2014-05-02	2020-10-14	UAB Research Foundation	Methods and compositions for diagnosis and treatment of meningitis
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
MA43072A (fr) *	2015-07-22	2018-05-30	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
BR112018008769A2 (pt) *	2015-10-30	2018-12-04	Genentech Inc	formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
CN108289951A (zh)	2015-10-30	2018-07-17	豪夫迈·罗氏有限公司	抗-因子d抗体和缀合物
JP2018536650A (ja)	2015-10-30	2018-12-13	ジェネンテック，インコーポレイテッド	抗ｄ因子抗体変異体コンジュゲート及びその使用
EP3666901A1 (en)	2015-10-30	2020-06-17	F. Hoffmann-La Roche AG	Methods of measuring factor d activity and potency of factor d inhibitors
KR20180104635A (ko)	2015-12-30	2018-09-21	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
EP3526248A4 (en)	2016-10-17	2020-07-08	Musc Foundation for Research Development	COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
EP3580241A4 (en) *	2017-02-10	2021-01-06	The Trustees Of The University Of Pennsylvania	ANTIFACTOR D ANTIBODIES AND USES THEREOF
EP3610010A4 (en) *	2017-04-14	2021-02-24	Kodiak Sciences Inc.	COMPLEMENT D-FACTOR ANTAGONIST ANTIBODIES AND THEIR CONJUGATES
GB2583560A (en)	2018-12-11	2020-11-04	Admirx Inc	Fusion protein constructs for complement associated disease
EP4041312A4 (en)	2019-10-10	2023-12-20	Kodiak Sciences Inc.	METHOD FOR TREATING AN EYE DISORDER

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5256642A (en)	1988-04-01	1993-10-26	The Johns Hopkins University	Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5456909A (en)	1992-08-07	1995-10-10	T Cell Sciences, Inc.	Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5861156A (en) *	1993-01-08	1999-01-19	Creative Biomolecules	Methods of delivering agents to target cells
US5856300A (en)	1994-05-12	1999-01-05	T Cell Sciences, Inc.	Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en)	1993-09-24	1997-10-21	Cytomed, Inc.	Chimeric proteins which block complement activation
US5627264A (en)	1994-03-03	1997-05-06	Alexion Pharmaceuticals, Inc.	Chimeric complement inhibitor proteins
DE69533921T2 (de)	1994-03-23	2005-12-01	Alexion Pharmaceuticals, Inc., New Haven	Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) *	1994-06-02	1997-10-21	The Johns Hopkins University	Method for preventing complement-dependent rejection of organ or tissue transplants
US7112327B2 (en) *	1998-02-20	2006-09-26	Tanox, Inc.	Inhibition of complement activation
US6956107B2 (en) *	1998-02-20	2005-10-18	Tanox, Inc.	Inhibitors of complement activation

1999
- 1999-02-19 EP EP08018816.2A patent/EP2033659B1/en not_active Expired - Lifetime
- 1999-02-19 CN CNA2007103002136A patent/CN101298481A/zh active Pending
- 1999-02-19 ES ES08018816.2T patent/ES2446930T3/es not_active Expired - Lifetime
- 1999-02-19 JP JP2000532147A patent/JP4437192B2/ja not_active Expired - Lifetime
- 1999-02-19 CN CNB998052566A patent/CN100366293C/zh not_active Expired - Lifetime
- 1999-02-19 EP EP15185734.9A patent/EP3056516A1/en not_active Withdrawn
- 1999-02-19 DK DK08018816.2T patent/DK2033659T3/da active
- 1999-02-19 KR KR10-2000-7008454A patent/KR100425965B1/ko not_active IP Right Cessation
- 1999-02-19 EP EP17156521.1A patent/EP3260467A1/en not_active Withdrawn
- 1999-02-19 DE DE69939813T patent/DE69939813D1/de not_active Expired - Lifetime
- 1999-02-19 SI SI9931073T patent/SI2033659T1/sl unknown
- 1999-02-19 DK DK99909512T patent/DK1054693T3/da active
- 1999-02-19 EP EP99909512A patent/EP1054693B8/en not_active Expired - Lifetime
- 1999-02-19 WO PCT/US1999/003566 patent/WO1999042133A1/en active IP Right Grant
- 1999-02-19 AU AU28700/99A patent/AU762050B2/en not_active Expired
- 1999-02-19 SI SI9931018T patent/SI1054693T1/sl unknown
- 1999-02-19 ES ES10182251.8T patent/ES2488819T3/es not_active Expired - Lifetime
- 1999-02-19 CA CA2321140A patent/CA2321140C/en not_active Expired - Lifetime
- 1999-02-19 PT PT99909512T patent/PT1054693E/pt unknown
- 1999-02-19 ES ES99909512T patent/ES2317689T3/es not_active Expired - Lifetime
- 1999-02-19 BR BR9909220-4A patent/BR9909220A/pt not_active IP Right Cessation
- 1999-02-19 EP EP10182251.8A patent/EP2277920B1/en not_active Expired - Lifetime
- 1999-02-19 EP EP14168816.8A patent/EP2848634A1/en not_active Withdrawn
- 1999-02-19 BR BRPI9909220A patent/BRPI9909220B1/pt unknown
- 1999-02-19 NZ NZ506920A patent/NZ506920A/en not_active IP Right Cessation
- 1999-02-19 AT AT99909512T patent/ATE412431T1/de active
2001
- 2001-10-04 HK HK01106981A patent/HK1036016A1/xx not_active IP Right Cessation
2006
- 2006-06-29 US US11/478,089 patent/US7439331B2/en not_active Expired - Fee Related
2008
- 2008-12-23 CY CY20081101490T patent/CY1108663T1/el unknown

Also Published As

Publication number	Publication date
EP2033659A2 (en)	2009-03-11
JP2002503706A (ja)	2002-02-05
ES2446930T3 (es)	2014-03-10
BR9909220A (pt)	2000-11-21
ES2317689T3 (es)	2009-04-16
EP2277920A3 (en)	2012-11-14
EP2033659A3 (en)	2009-08-19
US20060240020A1 (en)	2006-10-26
AU762050B2 (en)	2003-06-19
JP4437192B2 (ja)	2010-03-24
CY1108663T1 (el)	2014-04-09
EP1054693A4 (en)	2005-03-23
DK2033659T3 (da)	2014-02-17
US7439331B2 (en)	2008-10-21
NZ506920A (en)	2003-12-19
DK1054693T3 (da)	2008-12-08
EP3260467A1 (en)	2017-12-27
ATE412431T1 (de)	2008-11-15
WO1999042133A1 (en)	1999-08-26
CN101298481A (zh)	2008-11-05
EP1054693A1 (en)	2000-11-29
ES2488819T3 (es)	2014-08-29
SI1054693T1 (sl)	2009-04-30
CN1298308A (zh)	2001-06-06
SI2033659T1 (sl)	2014-03-31
EP2277920B1 (en)	2014-06-11
BRPI9909220B1 (pt)	2018-09-18
PT1054693E (pt)	2009-01-22
KR20010040585A (ko)	2001-05-15
EP2848634A1 (en)	2015-03-18
EP1054693B1 (en)	2008-10-29
EP3056516A1 (en)	2016-08-17
EP2277920A2 (en)	2011-01-26
KR100425965B1 (ko)	2004-04-06
CN100366293C (zh)	2008-02-06
EP1054693B8 (en)	2009-03-04
DE69939813D1 (de)	2008-12-11
EP2033659B1 (en)	2013-12-04
AU2870099A (en)	1999-09-06
CA2321140C (en)	2015-04-07
CA2321140A1 (en)	1999-08-26

Publication	Publication Date	Title
EP1054693B8 (en)	2009-03-04	Inhibitors of complement activation
PT1265929E (pt)	2009-10-15	Inibidores anti-c2/c2a de activação complementar
HK1225741A1 (zh)	2017-09-15	用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制
NO2006008I1 (no)	2006-08-07	Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
KR960704576A (ko)	1996-10-09	CD40에 대한 항체(Antibodies to CD40)
RS80704A (en)	2006-12-15	ANTI- av?6.ANTIBODIES
SG156547A1 (en)	2009-11-26	Human monoclonal antibodies to ctla-4
TW200722518A (en)	2007-06-16	Sc(fv)2 structural isomers
NZ611387A (en)	2015-05-29	Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
EP0751962A4 (en)	1997-05-21	METHODS AND COMPOSITIONS FOR INHIBITING THE ACTIVATION OF CD14-INDUCED CELLS
HRP20090527T1 (en)	2009-11-30	Nogo-a neutralising immunoglobulins for treatment of neurological diseases
UA89017C2 (uk)	2009-12-25	ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
IL162117A0 (en)	2005-11-20	Humanized collagen antibodies and methods utilizing the same
WO2002074251A3 (en)	2004-02-19	Monoclonal antibody therapy for pancreas cancer
IL139571A0 (en)	2002-02-10	A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
EP1468022A4 (en)	2005-12-21	NEW MONOCLONAL ANTIBODY AND LARVAL NEMATODIAN ANTIGENS
SE9501302D0 (sv)	1995-04-07	Antibodies for use in cancertherapy and diagnosis

Legal Events

Date	Code	Title	Description
2019-03-01	PE	Patent expired